191 related articles for article (PubMed ID: 25909885)
21. Metastatic Melanoma Patient-Derived Xenografts Respond to MDM2 Inhibition as a Single Agent or in Combination with BRAF/MEK Inhibition.
Shattuck-Brandt RL; Chen SC; Murray E; Johnson CA; Crandall H; O'Neal JF; Al-Rohil RN; Nebhan CA; Bharti V; Dahlman KB; Ayers GD; Yan C; Kelley MC; Kauffmann RM; Hooks M; Grau A; Johnson DB; Vilgelm AE; Richmond A
Clin Cancer Res; 2020 Jul; 26(14):3803-3818. PubMed ID: 32234759
[TBL] [Abstract][Full Text] [Related]
22. STK11 Prevents Invasion through Signal Transducer and Activator of Transcription 3/5 and FAK Repression in Cutaneous Melanoma.
Dzung A; Saltari A; Tiso N; Lyck R; Dummer R; Levesque MP
J Invest Dermatol; 2022 Apr; 142(4):1171-1182.e10. PubMed ID: 34757069
[TBL] [Abstract][Full Text] [Related]
23. Mitogen-activated protein kinase (MAPK) hyperactivation and enhanced NRAS expression drive acquired vemurafenib resistance in V600E BRAF melanoma cells.
Lidsky M; Antoun G; Speicher P; Adams B; Turley R; Augustine C; Tyler D; Ali-Osman F
J Biol Chem; 2014 Oct; 289(40):27714-26. PubMed ID: 25063807
[TBL] [Abstract][Full Text] [Related]
24. Inducible nitric oxide synthase expression in benign and malignant cutaneous melanocytic lesions.
Massi D; Franchi A; Sardi I; Magnelli L; Paglierani M; Borgognoni L; Maria Reali U; Santucci M
J Pathol; 2001 Jun; 194(2):194-200. PubMed ID: 11400148
[TBL] [Abstract][Full Text] [Related]
25. Expression and activation of matrix metalloproteinase-2 (MMP-2) and its co-localization with membrane-type 1 matrix metalloproteinase (MT1-MMP) correlate with melanoma progression.
Hofmann UB; Westphal JR; Zendman AJ; Becker JC; Ruiter DJ; van Muijen GN
J Pathol; 2000 Jul; 191(3):245-56. PubMed ID: 10878545
[TBL] [Abstract][Full Text] [Related]
26. Fatty acid synthase expression in cutaneous melanocytic neoplasms.
Kapur P; Rakheja D; Roy LC; Hoang MP
Mod Pathol; 2005 Aug; 18(8):1107-12. PubMed ID: 15920554
[TBL] [Abstract][Full Text] [Related]
27. Inducible nitric oxide synthase expression in melanoma: implications in lymphangiogenesis.
Massi D; De Nisi MC; Franchi A; Mourmouras V; Baroni G; Panelos J; Santucci M; Miracco C
Mod Pathol; 2009 Jan; 22(1):21-30. PubMed ID: 18660796
[TBL] [Abstract][Full Text] [Related]
28. The role of BPTF in melanoma progression and in response to BRAF-targeted therapy.
Dar AA; Nosrati M; Bezrookove V; de Semir D; Majid S; Thummala S; Sun V; Tong S; Leong SP; Minor D; Billings PR; Soroceanu L; Debs R; Miller JR; Sagebiel RW; Kashani-Sabet M
J Natl Cancer Inst; 2015 Feb; 107(5):. PubMed ID: 25713167
[TBL] [Abstract][Full Text] [Related]
29. Dual Covalent Inhibition of PKM and IMPDH Targets Metabolism in Cutaneous Metastatic Melanoma.
Zerhouni M; Martin AR; Furstoss N; Gutierrez VS; Jaune E; Tekaya N; Beranger GE; Abbe P; Regazzetti C; Amdouni H; Driowya M; Dubreuil P; Luciano F; Jacquel A; Tulic MK; Cluzeau T; O'Hara BP; Ben-Sahra I; Passeron T; Benhida R; Robert G; Auberger P; Rocchi S
Cancer Res; 2021 Jul; 81(14):3806-3821. PubMed ID: 34099492
[TBL] [Abstract][Full Text] [Related]
30. Differential inhibition of ex-vivo tumor kinase activity by vemurafenib in BRAF(V600E) and BRAF wild-type metastatic malignant melanoma.
Tahiri A; Røe K; Ree AH; de Wijn R; Risberg K; Busch C; Lønning PE; Kristensen V; Geisler J
PLoS One; 2013; 8(8):e72692. PubMed ID: 24023633
[TBL] [Abstract][Full Text] [Related]
31. Protease-activated receptor-1 (PAR-1) promotes the motility of human melanomas and is associated to their metastatic phenotype.
Silini A; Ghilardi C; Ardinghi C; Bernasconi S; Oliva P; Carraro F; Naldini A; Bani MR; Giavazzi R
Clin Exp Metastasis; 2010; 27(1):43-53. PubMed ID: 20084489
[TBL] [Abstract][Full Text] [Related]
32. Combining ERBB family and MET inhibitors is an effective therapeutic strategy in cutaneous malignant melanoma independent of BRAF/NRAS mutation status.
Das I; Wilhelm M; Höiom V; Franco Marquez R; Costa Svedman F; Hansson J; Tuominen R; Egyhàzi Brage S
Cell Death Dis; 2019 Sep; 10(9):663. PubMed ID: 31506424
[TBL] [Abstract][Full Text] [Related]
33. BRAFV600E cooperates with PI3K signaling, independent of AKT, to regulate melanoma cell proliferation.
Silva JM; Bulman C; McMahon M
Mol Cancer Res; 2014 Mar; 12(3):447-63. PubMed ID: 24425783
[TBL] [Abstract][Full Text] [Related]
34. Immunohistochemistry is highly sensitive and specific for the detection of NRASQ61R mutation in melanoma.
Massi D; Simi L; Sensi E; Baroni G; Xue G; Scatena C; Caldarella A; Pinzani P; Fontanini G; Carobbio A; Urso C; Mandalà M
Mod Pathol; 2015 Apr; 28(4):487-97. PubMed ID: 25341653
[TBL] [Abstract][Full Text] [Related]
35. HMG-CoA synthase 1 is a synthetic lethal partner of BRAF
Zhao L; Fan J; Xia S; Pan Y; Liu S; Qian G; Qian Z; Kang HB; Arbiser JL; Pollack BP; Kudchadkar RR; Lawson DH; Rossi M; Abdel-Wahab O; Merghoub T; Khoury HJ; Khuri FR; Boise LH; Lonial S; Chen F; Chen J; Lin R
J Biol Chem; 2017 Jun; 292(24):10142-10152. PubMed ID: 28468827
[TBL] [Abstract][Full Text] [Related]
36. AMPK activators inhibit the proliferation of human melanomas bearing the activated MAPK pathway.
Petti C; Vegetti C; Molla A; Bersani I; Cleris L; Mustard KJ; Formelli F; Hardie GD; Sensi M; Anichini A
Melanoma Res; 2012 Oct; 22(5):341-50. PubMed ID: 22588166
[TBL] [Abstract][Full Text] [Related]
37. Antitumor Activity of BRAF Inhibitor and IFNα Combination in BRAF-Mutant Melanoma.
Sabbatino F; Wang Y; Scognamiglio G; Favoino E; Feldman SA; Villani V; Flaherty KT; Nota S; Giannarelli D; Simeone E; Anniciello AM; Palmieri G; Pepe S; Botti G; Ascierto PA; Ferrone CR; Ferrone S
J Natl Cancer Inst; 2016 Jul; 108(7):. PubMed ID: 26851802
[TBL] [Abstract][Full Text] [Related]
38. Dual suppression of the cyclin-dependent kinase inhibitors CDKN2C and CDKN1A in human melanoma.
Jalili A; Wagner C; Pashenkov M; Pathria G; Mertz KD; Widlund HR; Lupien M; Brunet JP; Golub TR; Stingl G; Fisher DE; Ramaswamy S; Wagner SN
J Natl Cancer Inst; 2012 Nov; 104(21):1673-9. PubMed ID: 22997239
[TBL] [Abstract][Full Text] [Related]
39. The upregulated expression of RFC4 and GMPS mediated by DNA copy number alteration is associated with the early diagnosis and immune escape of ESCC based on a bioinformatic analysis.
Wang J; Luo FF; Huang TJ; Mei Y; Peng LX; Qian CN; Huang BJ
Aging (Albany NY); 2021 Sep; 13(17):21758-21777. PubMed ID: 34520390
[TBL] [Abstract][Full Text] [Related]
40. The fatty acid binding protein 7 (FABP7) is involved in proliferation and invasion of melanoma cells.
Slipicevic A; Jørgensen K; Skrede M; Rosnes AK; Trøen G; Davidson B; Flørenes VA
BMC Cancer; 2008 Sep; 8():276. PubMed ID: 18826602
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
